The biotechnology IPO market added another name this week as Scribe Therapeutics (NASDAQ: SCTX) priced an upsized initial public offering, raising approximately $128.7 million and…
July 24, 2026
NeuroSense Therapeutics is moving PrimeC one step closer to a Canadian regulatory filing, keeping its ALS story focused on a possible accelerated path to market….
July 22, 2026
Jaguar Health’s Crofelemer Gets Another Compassionate-Use Win in a Tiny but Critical Rare Disease Market
Jaguar Health is expanding the real‑world use of crofelemer, with another infant in the European Union set to receive the drug through compassionate use for…
July 21, 2026
Helus Hits Full Enrollment in Phase 3 APPROACH Study for Breakthrough Depression Drug HLP003
Helus Pharma (NASDAQ: HELP) has finished enrolling patients in its Phase 3 APPROACH trial of HLP003, a key step that clears the path toward late‑stage…
BioLineRx Ltd. (NASDAQ: BLRX) and Hemispherian AS have highlighted new preclinical data suggesting that their drug candidate GLIX1 may significantly boost the effectiveness of PARP…
July 17, 2026
Illuccix Japan Study Hits Full Enrollment as Telix Moves Closer to Prostate Cancer Imaging Approval
Telix Pharmaceuticals (NASDAQ: TLX) has hit a key clinical milestone, finishing patient enrollment in its Phase 3 Illuccix Japan study of TLX591‑Px for prostate cancer…
A reimbursement question that had hung over the stock for a year resolved in the company’s favor. Shares closed up about 35%. The policy affirms…
AtaiBeckley just had a breakout moment, with its share price soaring on news that Eli Lilly is in talks to buy the psychedelic drug developer….
Telix Pharmaceuticals (NASDAQ: $TLX) and St Vincent’s Hospital have started dosing the first patients in OPTIMAL‑e, a clinical trial bringing their next‑generation PSMA‑targeted radioligand therapy…
Glioblastoma Awareness Day 2026 lands under the theme “Honoring Every Story, Advancing Every Hope.” Four companies are testing immune-based approaches against the disease, each carrying…
The Advanced Research Projects Agency for Health (ARPA-H) is committing up to $160 million to scientists building platforms for highly personalized genetic treatments, with a…
Northwest Biotherapeutics Inc. (OTCQB: NWBO) is highlighting updated survival data from its Phase III trial of DCVax-L in glioblastoma that underline a key point: more…